Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25724155 | 0.73 | — | — | |
| SCHEMBL18133834 | 0.72 | MAPT (0.43) | MAPTTGFBR1 | |
| SCHEMBL25724223 | 0.71 | MAPT (0.33) | MAPT | |
| SCHEMBL17030767 | 0.71 | MAPT (0.58) | MAPT | |
| SCHEMBL22924152 | 0.71 | — | — | |
| SCHEMBL20850536 | 0.70 | MAPT (0.36) | MAPTTGFBR1 | |
| SCHEMBL19304042 | 0.70 | MAPT (0.39) | MAPTTGFBR1 | |
| SCHEMBL22924114 | 0.69 | METAP2 (0.36) | — | |
| SCHEMBL19115364 | 0.69 | MAPT (0.51) | MAPTTGFBR1 | |
| SCHEMBL22924153 | 0.67 | PROKR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPT 4598/4885MAPK14 669/4885TGFBR1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.